Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 10/20 | 0.48 |
| ▸ | CA2 | P00918 | 10/20 | 0.48 |
| ▸ | CA9 | Q16790 | 10/20 | 0.48 |
| ▸ | CA12 | O43570 | 9/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7780104 | 0.94 | PTGS2 (0.55) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL7779710 | 0.89 | RAB9A (0.57) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL7777584 | 0.89 | PTGS2 (0.63) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL7779573 | 0.88 | PTGS2 (0.64) | PTGS2PTGS1PKMNPC1RAB9A | |
| SCHEMBL7777871 | 0.86 | PTGS2 (0.58) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL8629992 | 0.86 | PKM (0.48) | PTGS2PTGS1PKMCA1CA2 | |
| SCHEMBL7779955 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL7773192 | 0.83 | CA9 (0.52) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL7778150 | 0.82 | PTGS2 (0.49) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL7779740 | 0.82 | CA1 (0.50) | PTGS2PTGS1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0772597-B1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1127878-A1 | 3,4 - substituted pyrazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6028072-A | 3,4-substituted pyrazoles for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0772597-A1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5580985-A | ANTIARTHRITIC AGENT; SIDE EFFECT REDUCTION | G. D. SEARLE & CO. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996003385-A1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5486534-A | 3,4-substituted pyrazoles for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-01-23 | — | — | US | disclosed |